The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or ...
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback